Copyright
©The Author(s) 2015.
World J Gastroenterol. Mar 7, 2015; 21(9): 2777-2785
Published online Mar 7, 2015. doi: 10.3748/wjg.v21.i9.2777
Published online Mar 7, 2015. doi: 10.3748/wjg.v21.i9.2777
Table 4 Comparison of survival rates in gastric cancer patients with or without expanded activated autologous lymphocyte immunotherapy
| Group | n | 1 yr survival rate (%)(95%CI) | 2-yr survival rate (%)(95%CI) | 3-yr survival rate (%)(95%CI) | 4-yr survival rate (%)(95%CI) | 5-yr survival rate (%)(95%CI) |
| Immunotherapy group | 42 | 80.95 | 54.35 | 41.1 | 36.54 | 25.05 |
| (69.08-92.83) | (39.16-69.54) | (25.79-56.41) | (20.52-52.55) | (7.78-42.33) | ||
| Control group | 42 | 61.9 | 33.33 | 16.67 | 11.11 | 11.11 |
| (47.22-76.59) | (19.08-47.59) | (5.40-27.94) | (0-22.75) | (0-22.75) | ||
| P value | > 0.05 | > 0.05 | > 0.05 | > 0.05 | > 0.05 |
- Citation: Zhang GQ, Zhao H, Wu JY, Li JY, Yan X, Wang G, Wu LL, Zhang XG, Shao Y, Wang Y, Jiao SC. Prolonged overall survival in gastric cancer patients after adoptive immunotherapy. World J Gastroenterol 2015; 21(9): 2777-2785
- URL: https://www.wjgnet.com/1007-9327/full/v21/i9/2777.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i9.2777